Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2013; 19(43): 7680-7695
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7680
Published online Nov 21, 2013. doi: 10.3748/wjg.v19.i43.7680
Figure 5 β-catenin siRNA synergized the inhibitory effects of 8-bromo-7-methoxychrysin.
8-bromo-7-methoxychrysin (BrMC) downregulated CD44 and CD133 expression in liver cancer stem cells in a concentration-dependent manner (A). β-catenin was highly expressed in CD133+ sphere forming cells (SFCs) and was downregulated by BrMC treatment (B). β-catenin siRNA decreased the protein level of β-catenin (C) and stem cell markers (E), and significantly inhibited self-renewal capacity (D) of CD133+ SFCs (mean ± SD, n = 3). aP < 0.05 vs CD133+ SFCs or control siRNA transfected CD133+ SFCs. BrMC enhanced β-catenin siRNA induced downregulation of β-catenin expression (F) and inhibition of self-renewal capacity (G) in CD133+ SFCs (mean ± SD, n = 3). aP < 0.05 vs CD133+ SFCs derived from the MHCC97 cell line. cP < 0.05 vs 0.1 μmol/L BrMC or β-catenin siRNA treated CD133+ SFCs.
-
Citation: Quan MF, Xiao LH, Liu ZH, Guo H, Ren KQ, Liu F, Cao JG, Deng XY. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells
via downregulation of β-catenin. World J Gastroenterol 2013; 19(43): 7680-7695 - URL: https://www.wjgnet.com/1007-9327/full/v19/i43/7680.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i43.7680